631 related articles for article (PubMed ID: 29309923)
1. Dermal fibroblast-to-myofibroblast transition sustained by αvß3 integrin-ILK-Snail1/Slug signaling is a common feature for hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders.
Zoppi N; Chiarelli N; Binetti S; Ritelli M; Colombi M
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt A):1010-1023. PubMed ID: 29309923
[TBL] [Abstract][Full Text] [Related]
2. Multifaced Roles of the αvβ3 Integrin in Ehlers-Danlos and Arterial Tortuosity Syndromes' Dermal Fibroblasts.
Zoppi N; Chiarelli N; Ritelli M; Colombi M
Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29587413
[TBL] [Abstract][Full Text] [Related]
3. Biological insights in the pathogenesis of hypermobile Ehlers-Danlos syndrome from proteome profiling of patients' dermal myofibroblasts.
Chiarelli N; Zoppi N; Ritelli M; Venturini M; Capitanio D; Gelfi C; Colombi M
Biochim Biophys Acta Mol Basis Dis; 2021 Apr; 1867(4):166051. PubMed ID: 33383104
[TBL] [Abstract][Full Text] [Related]
4. RNA-Seq of Dermal Fibroblasts from Patients with Hypermobile Ehlers-Danlos Syndrome and Hypermobility Spectrum Disorders Supports Their Categorization as a Single Entity with Involvement of Extracellular Matrix Degrading and Proinflammatory Pathomechanisms.
Ritelli M; Chiarelli N; Cinquina V; Zoppi N; Bertini V; Venturini M; Colombi M
Cells; 2022 Dec; 11(24):. PubMed ID: 36552803
[TBL] [Abstract][Full Text] [Related]
5. Matrix Metalloproteinases Inhibition by Doxycycline Rescues Extracellular Matrix Organization and Partly Reverts Myofibroblast Differentiation in Hypermobile Ehlers-Danlos Syndrome Dermal Fibroblasts: A Potential Therapeutic Target?
Chiarelli N; Zoppi N; Venturini M; Capitanio D; Gelfi C; Ritelli M; Colombi M
Cells; 2021 Nov; 10(11):. PubMed ID: 34831458
[TBL] [Abstract][Full Text] [Related]
6. Hypermobile Ehlers-Danlos syndromes: Complex phenotypes, challenging diagnoses, and poorly understood causes.
Gensemer C; Burks R; Kautz S; Judge DP; Lavallee M; Norris RA
Dev Dyn; 2021 Mar; 250(3):318-344. PubMed ID: 32629534
[TBL] [Abstract][Full Text] [Related]
7. Hypermobile Ehlers-Danlos syndrome (a.k.a. Ehlers-Danlos syndrome Type III and Ehlers-Danlos syndrome hypermobility type): Clinical description and natural history.
Tinkle B; Castori M; Berglund B; Cohen H; Grahame R; Kazkaz H; Levy H
Am J Med Genet C Semin Med Genet; 2017 Mar; 175(1):48-69. PubMed ID: 28145611
[TBL] [Abstract][Full Text] [Related]
8. Transcriptome-Wide Expression Profiling in Skin Fibroblasts of Patients with Joint Hypermobility Syndrome/Ehlers-Danlos Syndrome Hypermobility Type.
Chiarelli N; Carini G; Zoppi N; Dordoni C; Ritelli M; Venturini M; Castori M; Colombi M
PLoS One; 2016; 11(8):e0161347. PubMed ID: 27518164
[TBL] [Abstract][Full Text] [Related]
9. Healthcare experiences among adults with hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorder in the United States.
Estrella E; Frazier PA
Disabil Rehabil; 2024 Feb; 46(4):731-740. PubMed ID: 36772820
[TBL] [Abstract][Full Text] [Related]
10. Subtle differences in autonomic symptoms in people diagnosed with hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders.
Martinez KL; Mauss C; Andrews J; Saboda K; Huynh JM; Sanoja AJ; Jesudas R; Byers PH; Laukaitis CM
Am J Med Genet A; 2021 Jul; 185(7):2012-2025. PubMed ID: 33826221
[TBL] [Abstract][Full Text] [Related]
11. Developing a self-management intervention to manage hypermobility spectrum disorders (HSD) and hypermobile Ehlers-Danlos syndrome (hEDS): an analysis informed by behaviour change theory.
Bennett SE; Walsh N; Moss T; Palmer S
Disabil Rehabil; 2022 Sep; 44(18):5231-5240. PubMed ID: 34101520
[TBL] [Abstract][Full Text] [Related]
12. An acquired or heritable connective tissue disorder? A review of hypermobile Ehlers Danlos Syndrome.
Martin A
Eur J Med Genet; 2019 Jul; 62(7):103672. PubMed ID: 31102747
[TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics of patients with hypermobile type Ehlers-Danlos syndrome (hEDS) and generalized hypermobility spectrum disorders (G-HSD): an online survey.
Teran-Wodzinski P; Kumar A
Rheumatol Int; 2023 Oct; 43(10):1935-1945. PubMed ID: 37378685
[TBL] [Abstract][Full Text] [Related]
14. Looking back and beyond the 2017 diagnostic criteria for hypermobile Ehlers-Danlos syndrome: A retrospective cross-sectional study from an Italian reference center.
Ritelli M; Chiarelli N; Cinquina V; Vezzoli M; Venturini M; Colombi M
Am J Med Genet A; 2024 Feb; 194(2):174-194. PubMed ID: 37774134
[TBL] [Abstract][Full Text] [Related]
15. Hypermobile Ehlers-Danlos syndrome and disorders of the gastrointestinal tract: What the gastroenterologist needs to know.
Thwaites PA; Gibson PR; Burgell RE
J Gastroenterol Hepatol; 2022 Sep; 37(9):1693-1709. PubMed ID: 35750466
[TBL] [Abstract][Full Text] [Related]
16. Cellular and Molecular Mechanisms in the Pathogenesis of Classical, Vascular, and Hypermobile Ehlers‒Danlos Syndromes.
Chiarelli N; Ritelli M; Zoppi N; Colombi M
Genes (Basel); 2019 Aug; 10(8):. PubMed ID: 31409039
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular manifestations of hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders.
Rashed ER; Ruiz Maya T; Black J; Fettig V; Kadian-Dodov D; Olin JW; Mehta L; Gelb BD; Kontorovich AR
Vasc Med; 2022 Jun; 27(3):283-289. PubMed ID: 35000503
[No Abstract] [Full Text] [Related]
18. Ultrastructure study of skin fibroblasts in patients with Ehlers-Danlos Syndrome (EDS): preliminary results.
Celli M; Iacovino C; Febbo A; Lotti LV; Miraglia E; Celli L; Roberti V; Sernicola A; Zambrano A; Turchetti A; Vespa S; Giustini S
Clin Ter; 2020; 171(5):e431-e436. PubMed ID: 32901788
[TBL] [Abstract][Full Text] [Related]
19. Mast cell activation disease and immunoglobulin deficiency in patients with hypermobile Ehlers-Danlos syndrome/hypermobility spectrum disorder.
Brock I; Prendergast W; Maitland A
Am J Med Genet C Semin Med Genet; 2021 Dec; 187(4):473-481. PubMed ID: 34747107
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
